Treatment of nonmetastatic muscle-invasive bladder cancer
Agency for Healthcare Research and Quality (AHRQ)
Record ID 32015000843
English
Authors' recommendations:
NAC with cisplatin-based regimens improves survival in patients with muscle-invasive bladder cancer, and
extended lymph node dissection during cystectomy might be more effective than standard lymph node dissection for improving survival. More research is needed to clarify the effectiveness of bladder-sparing therapies versus radical cystectomy and to define patient subgroups for which such therapies are a potential option.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.effectivehealthcare.ahrq.gov/ehc/products/570/2093/bladder-cancer-muscle-invasive-executive-150629.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Urinary Bladder
- Neoplasm Invasiveness
- Carcinoma, Transitional Cell
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.